Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bupivacaine + hydrocortisone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intraarticular, Infiltration
01
Overview
A combination of bupivacaine, an amide local anesthetic, and hydrocortisone, a corticosteroid with anti-inflammatory properties. Bupivacaine works by blocking nerve impulse generation and conduction through voltage-gated sodium channels, while hydrocortisone reduces inflammation through inhibition of phospholipase A2. This combination provides both immediate pain relief from the anesthetic component and longer-lasting anti-inflammatory effects from the steroid component.
02
Targets
NaV (Voltage-gated sodium channels)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on bupivacaine + hydrocortisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bupivacaine + hydrocortisone.